AMGN: Amgen Inc. - Summary | Jitta

Amgen Inc.

NASDAQ:AMGN

Price
$251.06
Loss Chance
43.4%
5.76JITTA SCORE
24.01%Under Jitta Line
Jitta Ranking
58 / 939
730 / 4,286
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (39)
Recent Business Performance (37)
Financial Strength (56)
Return to Shareholders (94)
Competitive Advantage (65)
Jitta Signs
Revenue and EarningConsistent
Share RepurchaseEvery Year
CapExVery Low
Interest Coverage RatioVery Good
SG&A to SalesDecreasing
Recent Business PerformanceEarning decline 11.58% in the last year
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
5.76
24.01%
1.44
157.40%
2.30
292.60%
Biotechnology
6.53
51.61%
3.21
60.68%
7.12
56.18%
COMPANY DESCRIPTION
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; QIAGEN N.V.; Adaptive Biotechnologies; and Eli Lilly and Company, as well as has a strategic agreement with McKesson Corporation to help improve cancer care in community oncology settings. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.